scispace - formally typeset
B

Barbara N. Weissman

Researcher at Emory University

Publications -  135
Citations -  9006

Barbara N. Weissman is an academic researcher from Emory University. The author has contributed to research in topics: Arthritis & Rheumatoid arthritis. The author has an hindex of 42, co-authored 134 publications receiving 8404 citations. Previous affiliations of Barbara N. Weissman include Harvard University & Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

Risk factors for incident radiographic knee osteoarthritis in the elderly. The framingham study

TL;DR: Elderly persons at high risk of developing radiographic knee OA included obese persons, nonsmokers, and those who were physically active and factors not associated with the risk of OA including chondrocalcinosis and a history of hand OA.
Journal ArticleDOI

The incidence and natural history of knee osteoarthritis in the elderly, the framingham osteoarthritis study

TL;DR: In elderly persons, the new onset of knee OA is frequent and is more common in women than men, however, among the elderly, age may not affect new disease occurrence or progression.
Journal ArticleDOI

Effect of Very Low Birth Weight and Subnormal Head Size on Cognitive Abilities at School Age

TL;DR: In very-low-birth-weight infants, perinatal growth failure, as evidenced by a subnormal head circumference at eight months of age, is associated with poor cognitive function, academic achievement, and behavior at eight years of age.
Journal ArticleDOI

Relation of Dietary Intake and Serum Levels of Vitamin D to Progression of Osteoarthritis of the Knee among Participants in the Framingham Study

TL;DR: The hypothesis that the relative deficiency of vitamin D, as determined by dietary intake and serum levels, predisposes patients to progression of osteoarthritis of the knee is investigated.
Journal ArticleDOI

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

TL;DR: Two years of treatment with adalimumab did not slow radiographic progression in patients with AS, as assessed by the mSASSS scoring system, when compared with radiographic data from patients naïve to TNF antagonist therapy.